StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
24
This year
2
Publishing Date
2024 - 03 - 18
1
2024 - 01 - 16
1
2023 - 09 - 14
2
2023 - 06 - 06
1
2023 - 04 - 19
1
2023 - 02 - 02
1
2022 - 12 - 14
1
2022 - 10 - 17
1
2022 - 03 - 15
1
2022 - 02 - 04
1
2022 - 02 - 01
1
2021 - 10 - 13
1
2021 - 06 - 28
2
2021 - 06 - 21
1
2021 - 06 - 14
1
2021 - 06 - 08
1
2021 - 05 - 07
1
2021 - 04 - 12
1
2021 - 03 - 31
1
2021 - 03 - 16
1
2021 - 02 - 19
1
2020 - 12 - 15
1
Sector
Health services
1
Health technology
24
Tags
Alzheimer
5
Alzheimer's
5
Alzheimer's disease
4
Alzheimer’s
9
Anavex
23
Anavex®2-73
18
Biomarkers
5
Blarcamesine
2
Clinical trials
2
Clinical-trials-phase-ii
6
Clinical-trials-phase-iii
2
Companies
1
Conference
1
Correlation
2
Dating
1
Dementia
2
Disease
11
Enroll
1
International
1
Life
4
Life science
14
N/a
11
Parkinson
2
Parkinson's
1
Pdd-001
1
People
1
Pharm-country
3
Pharmaceutical
1
Phase 2
10
Phase 2/3
1
Phase 2b
5
Phase 3
3
Pipeline
1
Presentation
2
Results
1
Rett syndrome
7
Schizophrenia
2
Sciences
4
Space
1
Syndros
5
Therapy
1
Tiona
1
Topline
1
Treatment
5
Trial
21
Trials
1
Entities
4d molecular therapeutics inc
24
Abb ltd
72
Abbvie inc.
62
Actinium pharmaceuticals, inc.
28
Aldeyra therapeutics, inc.
38
Alnylam pharmaceuticals, inc.
38
Alterity therapeutics limited
26
Altra industrial motion corp.
23
Amgen inc.
25
Anavex life sciences corp.
24
Arcutis biotherapeutics, inc.
29
Arrival
26
Arrowhead pharmaceuticals, inc.
24
Astellas pharma inc
26
Astrazeneca plc
64
Beigene, ltd.
35
Biogen inc.
23
Biovie inc.
28
Bioxcel therapeutics, inc.
27
Bristol-myers squibb company
73
Clearside biomedical, inc.
24
Clene inc
25
Cnh industrial n.v.
69
Cybin inc
26
Cytokinetics, incorporated
29
Dynavax technologies corporation
28
Eli lilly and company
161
Enlivex therapeutics ltd.
26
Exelixis, inc.
28
Fortress biotech, inc.
41
Gates industrial corporation plc
25
Gilead sciences, inc.
48
Global industrial co
38
Honeywell international inc.
53
Horizon therapeutics public limited company
46
I-mab
34
Icon plc
43
Immix biopharma, inc.
26
Immutep limited
34
Incyte corporation
49
Johnson & johnson
203
Medtronic plc
25
Merck & company, inc.
72
Moleculin biotech, inc.
34
Novartis ag
34
Novo nordisk a/s
42
Ocugen, inc.
27
Orange
91
Pds biotechnology corporation
25
Pfizer, inc.
61
Plus therapeutics, inc.
35
Regeneron pharmaceuticals, inc.
44
Regenxbio inc.
29
Sanofi
311
Sellas life sciences group, inc.
24
Sorrento therapeutics, inc.
38
Stag industrial, inc.
32
Takeda pharmaceutical company limited
56
Tg therapeutics, inc.
27
Thermo fisher scientific inc
48
Symbols
APTX
1
AVXL
24
BIIB
1
BIVI
1
DNLI
1
LLY
1
NVO
1
VTGN
1
Exchanges
Nasdaq
24
Nyse
1
Crawled Date
2024 - 03 - 18
1
2024 - 01 - 16
1
2023 - 09 - 14
2
2023 - 06 - 06
1
2023 - 04 - 19
1
2023 - 02 - 02
1
2022 - 12 - 14
1
2022 - 10 - 17
1
2022 - 03 - 15
1
2022 - 02 - 04
1
2022 - 02 - 01
1
2021 - 10 - 13
1
2021 - 06 - 28
2
2021 - 06 - 21
1
2021 - 06 - 14
1
2021 - 06 - 08
1
2021 - 05 - 07
1
2021 - 04 - 12
1
2021 - 03 - 31
1
2021 - 03 - 16
1
2021 - 02 - 19
1
2020 - 12 - 15
1
Crawled Time
12:00
12
12:01
1
12:03
1
12:20
1
12:30
2
13:00
3
14:00
1
14:30
1
15:00
1
19:00
1
Source
www.anavex.com
4
www.biospace.com
13
www.globenewswire.com
6
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
entities :
Anavex life sciences corp.
save search
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Published:
2024-03-18
(Crawled : 12:00)
- globenewswire.com
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-33.27%
|
O:
0.0%
H:
0.78%
C:
-5.68%
anavex
life
sciences
schizophrenia
trial
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Published:
2024-01-16
(Crawled : 12:30)
- globenewswire.com
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-43.07%
|
O:
-0.5%
H:
0.86%
C:
0.34%
anavex
life
sciences
schizophrenia
trial
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology
Published:
2023-09-14
(Crawled : 12:30)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-55.48%
|
O:
4.18%
H:
5.14%
C:
-0.38%
anavex
disease
blarcamesine
alzheimer’s
trial
biomarkers
anavex®2-73
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Published:
2023-09-14
(Crawled : 12:00)
- globenewswire.com
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-55.48%
|
O:
4.18%
H:
5.14%
C:
-0.38%
anavex
disease
blarcamesine
alzheimer’s
trial
anavex®2-73
Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Published:
2023-06-06
(Crawled : 12:00)
- globenewswire.com
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-62.4%
|
O:
0.44%
H:
1.15%
C:
0.0%
life
sciences
trial
anavex
rett syndrome
anavex®2-73
phase 2
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published:
2023-04-19
(Crawled : 15:00)
- prnewswire.com
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
-25.69%
|
O:
-3.51%
H:
1.28%
C:
0.74%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
97.94%
|
O:
0.17%
H:
0.2%
C:
-0.02%
VTGN
|
$4.75
-1.66%
-1.68%
150K
|
Health Technology
|
10.25%
|
O:
0.0%
H:
2.59%
C:
-0.49%
DNLI
|
$15.55
-3.48%
-3.6%
940K
|
Health Technology
|
-38.06%
|
O:
-1.11%
H:
1.31%
C:
0.56%
BIVI
|
$0.5025
2.18%
2.13%
850K
|
Health Technology
|
-93.76%
|
O:
-0.24%
H:
4.29%
C:
0.49%
BIIB
|
$201.91
4.52%
4.32%
3.3M
|
Health Technology
|
-31.26%
|
O:
-0.39%
H:
0.4%
C:
-0.14%
APTX
|
$0.061
21.31%
7.8M
|
Health Services
|
-51.97%
|
O:
2.05%
H:
13.81%
C:
11.81%
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-58.0%
|
O:
-0.74%
H:
2.73%
C:
1.61%
disease
companies
parkinson's
pipeline
space
trial
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Published:
2023-02-02
(Crawled : 14:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-68.97%
|
O:
0.91%
H:
5.59%
C:
2.52%
anavex
anavex®2-73
trial
rett syndrome
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Published:
2022-12-14
(Crawled : 19:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-60.98%
|
O:
-0.69%
H:
3.46%
C:
1.73%
trial
alzheimer’s
anavex
phase 2b
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
Published:
2022-10-17
(Crawled : 12:20)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-67.83%
|
O:
4.43%
H:
14.0%
C:
12.83%
anavex
anavex®2-73
trials
sciences
disease
life
alzheimer’s
presentation
phase 2b
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Published:
2022-03-15
(Crawled : 12:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-66.17%
|
O:
0.4%
H:
6.32%
C:
5.24%
pdd-001
anavex
phase 2
dementia
anavex®2-73
parkinson
conference
presentation
disease
life science
international
tiona
biomarkers
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
Published:
2022-02-04
(Crawled : 14:30)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-66.67%
|
O:
-0.88%
H:
0.0%
C:
0.0%
anavex
treatment
anavex®2-73
trial
life science
phase 3
syndros
rett syndrome
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
Published:
2022-02-01
(Crawled : 13:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-71.7%
|
O:
1.24%
H:
0.0%
C:
-9.51%
anavex
treatment
trial
phase 3
anavex®2-73
syndros
rett syndrome
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s DiseaseThe Company anticipates topline data in the second half of 2022
Published:
2021-10-13
(Crawled : 13:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-80.22%
|
O:
0.17%
H:
3.65%
C:
2.32%
disease
alzheimer
phase 2
topline
life science
phase 2b
trial
anavex®2-73
anavex
alzheimer’s
alzheimer's
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial
Published:
2021-06-28
(Crawled : 13:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-86.22%
|
O:
20.0%
H:
6.06%
C:
-2.83%
phase 2
correlation
life science
trial
anavex®2-73
anavex
biomarkers
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
Published:
2021-06-28
(Crawled : 12:00)
- anavex.com
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-86.22%
|
O:
20.0%
H:
6.06%
C:
-2.83%
disease
treatment
phase 2
dementia
correlation
parkinson
life science
trial
anavex®2-73
anavex
biomarkers
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published:
2021-06-21
(Crawled : 12:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-84.6%
|
O:
8.67%
H:
15.75%
C:
4.61%
treatment
phase 2
life science
trial
anavex®2-73
anavex
syndros
biomarkers
rett syndrome
Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease
Published:
2021-06-14
(Crawled : 12:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-78.0%
|
O:
7.74%
H:
33.14%
C:
25.69%
disease
alzheimer
treatment
dating
life science
anavex®2-73
anavex
alzheimer’s
alzheimer's disease
alzheimer's
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Published:
2021-06-08
(Crawled : 12:00)
- biospace.com/
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-76.71%
|
O:
4.51%
H:
0.41%
C:
-0.46%
disease
alzheimer
phase 2
life science
phase 2b
trial
anavex®2-73
anavex
enroll
alzheimer’s
alzheimer's disease
alzheimer's
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
Published:
2021-05-07
(Crawled : 12:00)
- anavex.com
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-70.53%
|
O:
-0.35%
H:
1.99%
C:
-1.91%
clinical trials
life science
trial
anavex
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
Published:
2021-04-12
(Crawled : 12:00)
- anavex.com
AVXL
|
$3.4
-7.61%
-8.24%
2M
|
Health Technology
|
-76.63%
|
O:
-0.07%
H:
1.17%
C:
-8.85%
phase 2
phase 2/3
results
life science
trial
anavex®2-73
anavex
syndros
rett syndrome
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.